Ironwood Pharmaceuticals
IRWD
167 hedge funds and large institutions have $2.78B invested in Ironwood Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 63 increasing their positions, 51 reducing their positions, and 16 closing their positions.
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
29% more call options, than puts
Call options by funds: $4.66M | Put options by funds: $3.6M
24% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 51
11% more capital invested
Capital invested by funds: $2.5B → $2.78B (+$287M)
3% more funds holding
Funds holding: 162 → 167 (+5)
0.03% more ownership
Funds ownership: 131.42% → 131.45% (+0.03%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$138M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$39.2M |
| 3 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$19.5M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$14.7M |
| 5 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$43.8M |
| 2 |
O
OrbiMed
New York
|
-$25.7M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$14.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCIA
176
Campbell & Co Investment Adviser
Baltimore,
Maryland
| – | -$245K | -17,173 | Closed |
|
177
Squarepoint
New York
| – | -$221K | -15,459 | Closed |
|
|
GCA
178
Gideon Capital Advisors
New York
| – | -$191K | -13,387 | Closed |
|
|
GKWIM
179
Gerber Kawasaki Wealth & Investment Management
Santa Monica,
California
| – | -$165K | -12,010 | Closed |
|
|
AIM
180
Acrospire Investment Management
Chicago,
Illinois
| – | -$81K | -5,644 | Closed |
|
|
CSS
181
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$50K | -3,504 | Closed |
|
|
SCM
182
Segantii Capital Management
Hong Kong
| – | -$49K | -3,463 | Closed |
|
IRWD Hedge Fund Activity: Q2 2017 in Review
167 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2017, worth a combined $2.78B — up 11% from $2.5B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new IRWD positions and 16 closed out — a net gain of 6 holders — while 63 added to existing stakes and 51 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $138M. The largest seller was Adage Capital Partners, cutting an estimated $43.8M.
- 167 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2017, up from 162 in Q1 2017.
- Funds reported $2.78B of Ironwood Pharmaceuticals stock for Q2 2017, up 11% quarter-over-quarter.
- 22 funds opened new Ironwood Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of +6 holders.
- The largest Ironwood Pharmaceuticals buyer in Q2 2017 was Janus Henderson Group, an estimated $138M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2017 was Adage Capital Partners, an estimated $43.8M sold.
Based on aggregated 13F filings for Q2 2017.